Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections

用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体

基本信息

  • 批准号:
    10707403
  • 负责人:
  • 金额:
    $ 68.83万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-19 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Human parainfluenza virus (PIV) and metapneumovirus (MPV) are common causes of lower respiratory tract infections in infants and young children, and major causes of respiratory illness in immune compromised adults and the elderly. Unfortunately, there are no therapy or vaccine for either viruses, and only supportive medical care is available. Interestingly, PIV and MPV share many pathological and clinical manifestations as Respiratory Syncytial Virus (RSV). Indeed, neither PIV nor MPV are known to cause viremia in the blood of infected patients, indicating both infections are strictly localized in the airways similar to RSV that shed progeny viruses exclusively from the apical surface of infected cells. Such unique pathophysiology implies progeny viruses must traverse airway mucus (AM) before spreading to neighboring cells. This in turn motivated us to develop a pathogen-specific antiviral that could physically limit the spread of the infections within the airways. We recently discovered a novel Ab effector function in mucus – trapping individual pathogens in mucus based on carefully-tuned affinity between IgG-Fc and mucins – and developed a platform for enhancing mAb function at mucosal surfaces. We hypothesize that “muco-trapping” mAb delivered to the airways can directly intervene with the viral life cycle by intercepting and trapping shed progeny viruses in AM, rapidly eliminate trapped viruses from the airways by natural mucociliary clearance, and enable effective therapy in vivo. In support of this strategy, we engineered mAbs that potently trap RSV in AM, and showed that nebulized delivery of “muco-trapping” mAb to RSV-infected neonatal lambs beginning on Day 3 post infection effectively reduced the infectious viral load in lung tissues to non-detectible levels within 3 days, with viral RNA in bronchial tissues reduced by 11-fold compared to vehicle control. These results motivated us to explore whether a similar approach may be effective in treating PIV and MPV infections. In support of this application, we have engineered antibodies with picomolar affinity to diverse strains of both viruses, and demonstrated that we could effectively trap viruses in human AM and limit spread of infection in vitro in well-differentiated human airway epithelium (WD-HAE) grown at the air-liquid interface. In this proposal, we will continue our work with affinity maturation using mammalian and yeast display to produce high affinity mAb that broadly bind and neutralize diverse strains of PIV and MPV (Aim 1). We will validate whether these mAbs can trap PIV and MPV in fresh undiluted human AM, and whether they can inhibit the spread of pre-established PIV and MPV infections in WD-HAE cultures (Aim 2). We will then advance the lead mAb for both viruses for evaluation in a hamster nasal infection model (Aim 3). By enabling enhanced mAb function in mucus secretions, we expect we will help pave the way for improved, molecularly-targeted therapies and prophylaxis against a broad spectrum of pathogens across all major mucosal surfaces, providing a powerful option addressing the current gap in pharmacological interventions for respiratory infections.
人副流感病毒(PIV)和偏肺病毒(MPV)是下呼吸道感染的常见原因。 婴儿和幼儿的呼吸道感染,以及免疫受损儿童呼吸道疾病的主要原因 成年人和老年人。不幸的是,目前还没有针对这两种病毒的治疗方法或疫苗, 提供医疗护理。有趣的是,PIV和MPV有许多共同的病理和临床表现, 呼吸道合胞病毒(RSV)。事实上,PIV和MPV都不知道会导致血液中的病毒血症, 感染的患者,这表明这两种感染都严格局限于呼吸道,类似于RSV, 病毒只从受感染细胞的顶端表面传播。这种独特的病理生理学意味着后代 病毒在扩散到邻近细胞之前必须穿过气道粘液(AM)。这反过来又促使我们 开发一种病原体特异性的抗病毒药物,可以在物理上限制呼吸道内感染的传播。 我们最近在粘液中发现了一种新的抗体效应子功能--在粘液中捕获单个病原体 基于IgG-Fc和粘蛋白之间的精心调节的亲和力-并开发了一个平台,用于增强mAb 在粘膜表面起作用。我们假设,递送到气道的“粘膜捕获”mAb可以直接 通过在AM中拦截和诱捕脱落的子代病毒来干预病毒的生命周期, 通过自然的粘膜纤毛清除将病毒从气道中捕获,并能够在体内进行有效的治疗。在 为了支持这一策略,我们设计了在AM中有效捕获RSV的mAb,并表明雾化吸入的 从感染后第3天开始向RSV感染的新生羔羊有效递送“粘膜捕获”mAb 在3天内将肺组织中的感染性病毒载量降低到不可检测的水平, 与溶剂对照相比,支气管组织中的细胞数减少了11倍。这些结果促使我们去探索 类似的方法是否可以有效治疗PIV和MPV感染。为了支持这项申请, 我们已经设计了对两种病毒的不同毒株具有皮摩尔亲和力的抗体,并证明, 我们可以有效地将病毒捕获在人AM中,并限制感染在高分化人类中的体外传播, 气道上皮(WD HAE)生长在气液界面。 在这个建议中,我们将继续我们的工作与亲和力成熟使用哺乳动物和酵母展示 以产生广泛结合和中和PIV和MPV的不同毒株的高亲和力mAb(目的1)。我们将 验证这些mAb是否可以捕获新鲜未稀释的人AM中的PIV和MPV,以及它们是否可以抑制 预先建立的PIV和MPV感染在WD-HAE培养物中的传播(目的2)。然后我们将推进 用于仓鼠鼻感染模型评价的两种病毒的先导mAb(目的3)。通过增强 mAb在粘液分泌物中的功能,我们希望我们将有助于为改善分子靶向 治疗和预防所有主要粘膜表面的广谱病原体, 这是一个解决目前呼吸道感染药物干预差距的有力选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Samuel Lai其他文献

Samuel Lai的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Samuel Lai', 18)}}的其他基金

Engineering Siglec15/TGF-beta targeted bispecific antibodies that modulate the tumor microenvironment and enhances T-cell immunotherapy against pancreatic cancer
工程化 Siglec15/TGF-β 靶向双特异性抗体可调节肿瘤微环境并增强针对胰腺癌的 T 细胞免疫治疗
  • 批准号:
    10651442
  • 财政年份:
    2023
  • 资助金额:
    $ 68.83万
  • 项目类别:
Engineered “muco-trapping” antibodies for inhaled therapy of parainfluenza and human metapneumovirus infections
用于副流感和人类偏肺病毒感染吸入治疗的工程化“粘膜捕获”抗体
  • 批准号:
    10587723
  • 财政年份:
    2022
  • 资助金额:
    $ 68.83万
  • 项目类别:
Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
  • 批准号:
    10428467
  • 财政年份:
    2020
  • 资助金额:
    $ 68.83万
  • 项目类别:
Engineering bispecific antibodies for non-hormonal contraception
用于非激素避孕的双特异性抗体工程
  • 批准号:
    10618849
  • 财政年份:
    2020
  • 资助金额:
    $ 68.83万
  • 项目类别:
Overcoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeutics
克服抗 PEG 免疫,恢复 PEG 化治疗的延长循环和功效
  • 批准号:
    10181024
  • 财政年份:
    2018
  • 资助金额:
    $ 68.83万
  • 项目类别:
Artificial neural networks for high performance, fully automated particle tracking analysis even at low signal-to-noise regimes
人工神经网络即使在低信噪比条件下也能实现高性能、全自动粒子跟踪分析
  • 批准号:
    9347679
  • 财政年份:
    2017
  • 资助金额:
    $ 68.83万
  • 项目类别:
Prevalence and characteristics of anti-PEG antibodies in humans
人类抗 PEG 抗体的流行率和特征
  • 批准号:
    8622684
  • 财政年份:
    2014
  • 资助金额:
    $ 68.83万
  • 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
  • 批准号:
    8803845
  • 财政年份:
    2014
  • 资助金额:
    $ 68.83万
  • 项目类别:
Optimizing Plantibodies for Trapping HIV and HSV in Cervicovaginal Mucus
优化 Plantibodies 以捕获宫颈阴道粘液中的 HIV 和 HSV
  • 批准号:
    8515320
  • 财政年份:
    2013
  • 资助金额:
    $ 68.83万
  • 项目类别:
Trapping HIV in mucus with IgG antibodies
用 IgG 抗体将 HIV 捕获在粘液中
  • 批准号:
    8208988
  • 财政年份:
    2011
  • 资助金额:
    $ 68.83万
  • 项目类别:

相似海外基金

Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
  • 批准号:
    MR/Z503605/1
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
  • 批准号:
    2336167
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
  • 批准号:
    2402691
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
  • 批准号:
    2341428
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
  • 批准号:
    24K12150
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
  • 批准号:
    DE240100561
  • 财政年份:
    2024
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
  • 批准号:
    10065645
  • 财政年份:
    2023
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
  • 批准号:
    23K09542
  • 财政年份:
    2023
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
  • 批准号:
    23K07552
  • 财政年份:
    2023
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
  • 批准号:
    23K07559
  • 财政年份:
    2023
  • 资助金额:
    $ 68.83万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了